Reshape Lifesciences (STU:24O0) COGS-to-Revenue : 0.40 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences COGS-to-Revenue?

Reshape Lifesciences's Cost of Goods Sold for the three months ended in Mar. 2024 was €0.72 Mil. Its Revenue for the three months ended in Mar. 2024 was €1.79 Mil.

Reshape Lifesciences's COGS to Revenue for the three months ended in Mar. 2024 was 0.40.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Reshape Lifesciences's Gross Margin % for the three months ended in Mar. 2024 was 59.96%.

Reshape Lifesciences COGS-to-Revenue Historical Data

The historical data trend for Reshape Lifesciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences COGS-to-Revenue Chart

Reshape Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.38

0.45

0.39

0.36

Reshape Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.46	0.47	0.40	0.07	0.40

Reshape Lifesciences COGS-to-Revenue Calculation

Reshape Lifesciences's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.87	/	7.958
	=	0.36

Reshape Lifesciences's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.716	/	1.788
	=	0.40

Reshape Lifesciences (STU:24O0) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Reshape Lifesciences's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.716 / 1.788
	=	59.96 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Reshape Lifesciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Reshape Lifesciences (STU:24O0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (STU:24O0) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

RSLS:USA

Address

1001 Calle Amanecer, San Clemente, CA, USA, 92673

Website

https://www.reshapelifesciences.com

Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Reshape Lifesciences (STU:24O0) Headlines

No Headlines